Androgen Hormone Optimization Research for Chronic Diseases

Understand the role of androgen hormone optimization for chronic diseases in your health journey. Find insights and solutions here.

Abstract

As a clinician working at the intersection of functional and integrative medicine, I synthesize contemporary, evidence-based insights on testosterone, estradiol, dihydrotestosterone (DHT), and progesterone across men and women. Drawing on modern research methods and leading meta-analyses, I clarify why long-standing myths about testosterone and prostate cancer persist, explain the prostate saturation model, and outline a practical, patient-centered approach to hormone optimization that protects the brain, bone, metabolism, and cardiovascular system. I also discuss receptor-level physiology (androgen and estrogen receptors, ERα/ERβ), the impact of androgen deprivation therapy (ADT) on cardiometabolic and cognitive risks, differences between anabolic steroids and physiologic testosterone therapy, and the clinical role of bioidentical hormone delivery routes (transdermal, pellets) for safer pharmacokinetics. Throughout, I integrate clinical observations from my practice and professional outreach to help clinicians and patients navigate safe, effective hormone care using validated symptom scales, thoughtful monitoring, and individualized targets that respect free-hormone physiology rather than population reference ranges.

Why Hormone Signals Matter: The Physiology-First Lens

Hormone signals orchestrate systemic physiology, shaping brain function, bone remodeling, muscle protein synthesis, insulin sensitivity, immune balance, and vascular integrity. In clinical practice, missteps such as blanket suppression of DHT, conflating anabolic-androgenic steroids (AAS) with therapeutic testosterone, or chasing total testosterone numbers instead of free hormone availability create predictable harms. My approach begins with a physiology-first lens:

• Key principle: Restore what biology requires, avoid unnecessary blockade of physiologic conversions, and monitor multidimensional outcomes (mood, metabolic markers, bone, vasculature).
• Clinical impact: When we correct androgen and estrogen signaling thoughtfully, downstream systems recalibrate: patients report sharper cognition, resilient mood, improved insulin sensitivity, and better vascular function.

In my clinics, I routinely see men and women labeled “normal” by reference ranges who exhibit clear deficiency phenotypes. The solution is not symptom-by-symptom patchwork; it is targeted endocrine restoration with evidence-based safeguards (see clinical updates and perspectives at PushAsRx and my professional profile on LinkedIn).

The Androgen–Estrogen Axis: Testosterone, DHT, and Estradiol

Testosterone signals through the androgen receptor (AR) to govern transcriptional programs tied to protein synthesis, mitochondrial biogenesis, AMPK/mTOR balance, and vascular tone. Testosterone also converts into two crucial metabolites:

• Dihydrotestosterone (DHT) via 5-alpha-reductase
• Estradiol (E2) via aromatase

Each derivative has distinct receptor affinities and tissue distributions:

• DHT: Roughly fivefold higher AR affinity than testosterone; potent effects in prostate, external genitalia, skin, hair follicles, and CNS regions.
• Estradiol (E2): Binds ERα and ERβ, which are widely expressed in the brain, bone, vasculature, and immune cells; essential in men for bone mineralization, endothelial function, and aspects of libido and mood.

Why this physiology matters clinically:

• Blocking physiologic conversions can backfire. For men who rely on robust CNS DHT signaling, indiscriminate use of 5-alpha-reductase inhibitors (e.g., finasteride) can precipitate loss of libido, anorgasmia, depressive symptoms, and erectile rigidity—despite “normal” total testosterone. I frequently see this pattern in 30- to 40-year-old men prescribed finasteride for hair loss who present with neurosexual dysfunction once DHT is driven near zero.

Receptors Everywhere: Integrating Brain, Vascular, Bone, and Muscle Health

Androgen and estrogen receptors are ubiquitous:

• Brain (PFC, hippocampus, amygdala): Modulates dopamine, serotonin, GABA, synaptic plasticity, and neuroinflammation; essential for executive function, mood, and memory.
• Vascular endothelium: AR and ER enhance eNOS activity, nitric oxide availability, and reduce oxidative stress; they improve vascular stiffness and perfusion.
• Bone: Receptors regulate osteoblast and osteoclast dynamics; estradiol suppresses bone resorption by increasing osteoprotegerin and reducing RANKL.
• Skeletal muscle: AR activation boosts protein synthesis and satellite cell function, increasing lean mass and metabolic resilience.

Practical takeaway:

• Symptom clusters are physiologic. Low libido, depressed mood, reduced exercise tolerance, bone loss, insulin resistance, and sexual dysfunction often co-occur because the same receptor systems are under-signaled across tissues. Treating root endocrine deficits typically outperforms multi-drug symptom management.

Respecting Physiology: Why Blanket DHT Suppression Can Harm. DHT’s high AR affinity serves as a physiologic amplifier of testosterone’s effects in target tissues:

• Clinical observation: The sequence is common: finasteride for hair, an SSRI for premature ejaculation, then emerging blunted affect and erectile issues. Labs often reveal normal total testosterone but very low DHT and sometimes reduced free testosterone due to SSRI-induced SHBG shifts. Stepwise de-prescribing, targeted androgen support, and psychosexual counseling can reverse much of the dysfunction—sometimes gradually.
• Mechanistic logic: Altered AR coactivators, neurosteroid shifts, and reduced penile tissue androgenicity likely contribute. The lesson is simple: respect physiologic conversion unless a pressing urologic indication exists and informed consent covers sexual and neurobehavioral risks.

Cardiovascular and Metabolic Effects of Optimized Testosterone

In hypogonadal men, physiologic testosterone replacement therapy (TRT) often yields:

• Body composition: Increased lean mass, reduced visceral fat
• Insulin sensitivity: Improved HOMA-IR; A1c reductions in some cohorts
• Lipid parameters: Lower triglycerides variably; HDL changes are mixed; LDL particle quality may improve with better metabolic health
• Endothelial function: Enhanced flow-mediated dilation
• Inflammation: Lower CRP and cytokines in select studies

Mechanistic underpinnings:

• AR signaling upregulates GLUT4 translocation, enhances mitochondrial oxidative capacity, and modulates AMPK/mTOR signaling, thereby favoring efficient substrate utilization.
• Endothelial AR/ER convergence on eNOS increases nitric oxide bioavailability, improving vascular resistance and perfusion.
• Adipose effects: Testosterone reduces adipogenesis and may shift macrophages toward less inflammatory phenotypes.

Evidence in context:

• Meta-analyses and cohort data link low testosterone to higher all-cause mortality, cardiovascular events, and incidence of type 2 diabetes, whereas appropriately monitored TRT in deficient men often shows neutral to favorable cardiovascular signals when hematocrit, blood pressure, and comorbidities are managed (Corona et al., 2018; Rosano et al., 2020). Conversely, men on ADT exhibit increased diabetes, metabolic syndrome, and MACE (Nguyen et al., 2015; Margel et al., 2019).

Brain Health and Androgens: Dementia, Mood, and Neuroinflammation

The brain responds dynamically to sex steroids:

• Low androgen states are associated with a higher incidence of cognitive decline and dementia, including Alzheimer’s disease risk elevations in men at the lowest testosterone deciles.
• Depressive and anxiety symptoms worsen with androgen deficiency via impacts on monoamines, neuroinflammation, and synaptic plasticity.

Mechanisms:

• Testosterone and estradiol regulate BDNF, synaptic density, and microglial activation; estradiol’s anti-inflammatory effects in microglia and astrocytes are notable.
• ADT may accelerate white matter changes and hippocampal atrophy by removing trophic support and worsening insulin resistance and vascular risk, each contributing to neurodegeneration.

Clinical reasoning:

• The real question is not” Is the lab normal?” but “Is it optimal?” Men in the lowest quintiles of testosterone show substantially higher dementia risk relative to higher quintiles. Risk stratification must integrate symptoms, free hormone physiology, and comorbidities.

Normal Range vs Optimal Range: Why Reference Intervals Mislead

A reference range is statistical, not a health target:

• Ranges capture the central 95% of a lab’s sample population, often including individuals with obesity, chronic illness, and metabolic dysfunction.
• A 55-year-old man with 350 ng/dL total testosterone and disabling symptoms may sit at the 10th–20th percentile for his age, where risk and symptoms rise.

My clinical standard:

• Focus on free testosterone and SHBG alongside total testosterone; interpret these results in the context of estradiol/DHT balance and symptoms.
• Aim for an individualized optimal window, often between the 75th and 95th percentile for age, when safe and aligned with symptom relief and biomarker improvement.
• Monitor hematocrit/hemoglobin, PSA, lipids, BP, mood/cognition, and sleep apnea.

Why avoid overcorrection:

• Excess estradiol from aromatization can cause gynecomastia and fluid retention; indiscriminate aromatase inhibitors may harm bone and vascular health. Over-suppressing DHT can impair sexual and neurobehavioral functions. The aim is balanced physiology, not maximal androgenization.

Prostate Health and Testosterone: The Saturation Model

The prostate saturation model refutes the persistent myth that testosterone “feeds” prostate cancer:

• AR saturation in prostate tissue occurs at modest testosterone levels (often total T around 240–300 ng/dL; free T thresholds vary). Beyond saturation, additional testosterone adds minimal intraprostatic stimulation (Morgentaler & Traish, 2009).
• In men above saturation, raising testosterone within physiologic bounds does not linearly increase prostate growth or PSA.

Clinical implications:

• If PSA rises meaningfully after initiating TRT in a man already above saturation thresholds, consider prostatitis, BPH changes, or occult malignancy rather than reflexively blaming testosterone.
• Multiple cohort studies and meta-analyses show no increased prostate cancer incidence in men on TRT compared with untreated men; men with lower endogenous testosterone may even present with higher-grade disease (Khera et al., 2020).

My protocol:

• Baseline PSA, DRE where appropriate, prostate and family history, race, and metabolic risk.
• After initiating TRT: PSA baseline, recheck at ~6–12 weeks, then at 3–6 month intervals during year one, and at least annually thereafter.
• If PSA changes: assess for infection/inflammation, transient fluctuations, and coordinate with urology.

Distinguishing Therapeutic Testosterone from Anabolic Steroid Misuse

Decades of policy conflated AAS cycles with physiologic TRT for hypogonadism. They are fundamentally different:

• AAS misuse uses supraphysiologic doses of synthetic derivatives with distinct pharmacology and risks (thrombosis, dyslipidemia, hepatic strain).
• Physiologic TRT restores normal receptor signaling within sex- and age-appropriate ranges and is monitored for safety.

Clinical consequence:

• Avoiding TRT due to scheduling rules or misunderstanding leaves patients untreated. My role is to educate teams, document physiologic ranges, and monitor structured safety outcomes so patients receive etiologic therapy rather than symptom-chasing polypharmacy.

Route of Administration: Why Transdermal and Pellets Often Outperform Oral

Route matters for pharmacokinetics and safety:

• Oral estrogens undergo first-pass hepatic metabolism, inducing clotting factors and SHBG, elevating thrombotic risk and blunting skeletal/vascular benefits in susceptible patients.
• Transdermal estradiol offers physiologic serum patterns with less hepatic induction, improving endothelial function and bone outcomes (The NAMS 2023 Position Statement, 2023).
• Pellets provide steady-state kinetics; properly dosed estradiol and testosterone pellets produce low-variance plasma levels, reducing peak–trough instability and aligning with CNS and skeletal receptor biology (Bui et al., 2020).

In women with high SHBG, transdermal routes minimize further SHBG induction, making it easier to achieve adequate free testosterone for symptom relief.

Women’s Androgen Care: SHBG, Free Testosterone, and Pellets

Women frequently present with androgen-related symptoms despite “normal” total testosterone:

• SHBG is the gatekeeper; high SHBG sequesters testosterone, lowering free/bioavailable fractions and tissue signaling.
• Elevators of SHBG include oral estrogens, certain antidepressants, thyroid excess, liver conditions, and aging.

My workflow:

• Measure total testosterone, SHBG, and calculate free/bioavailable testosterone (equilibrium dialysis or validated equations).
• When SHBG is high, restoring function often requires adjusting total testosterone to achieve physiologic free testosterone without masculinizing side effects.
• Favor transdermal estradiol to avoid hepatic SHBG induction; consider pellets for patients who prefer steady delivery and improved adherence.
• In women with an intact uterus and systemic estradiol, ensure bioidentical progesterone to protect the endometrium.

Clinical patterns from my practice:

• Women on oral estrogens or SSRIs/SNRIs often have stubborn symptoms due to high SHBG; switching to transdermal estradiol and titrating testosterone to free/bioavailable targets consistently improves libido, energy, cognition, and exercise recovery.
• Pellets reduce the daily management burden and provide smoother pharmacokinetics; we individualize the dose based on weight, SHBG, symptom intensity, and prior responses.

Consensus and safety:

• Therapeutic testosterone in women, dosed to female physiologic ranges, can improve sexual function and mood with neutral cardiovascular signals when monitored (Davis et al., 2019; Islam et al., 2019).
• Avoid synthetic progestins that antagonize AR; prefer bioidentical progesterone for breast, brain, and endometrial balance.

Bone Health: Hormones, Vitamin D3/K2, and Remodeling Quality

Bone strength depends on density and microarchitecture:

• Estradiol suppresses osteoclastogenesis (reducing RANKL, increasing osteoprotegerin), curbing resorption.
• Progesterone supports osteoblast maturation; testosterone directly stimulates osteoblast activity and, via aromatization, provides local estradiol to bone (Finkelstein et al., 2016).
• Vitamin D3 boosts calcium absorption and osteoblast differentiation; Vitamin K2 activates osteocalcin and matrix Gla-protein, directing calcium into bone and protecting vasculature (Kawashima et al., 2020; Pilz et al., 2022).

My bone protocol:

• Ensure D3/K2 sufficiency, resistance training, protein adequacy, and appropriately titrated bioidentical estradiol/progesterone (women) and testosterone (men and select women).
• Reassess bone density every ~36 months; track P1NP and CTX when indicated.
• Focus on improving both density and quality, recognizing that some agents increase BMD without strengthening microarchitecture—a rationale for incorporating anabolic hormone signaling and load-bearing exercise (Cummings et al., 2018).

Testosterone and the Heart: Clarifying Risk vs Benefit

Physiologic testosterone benefits vascular biology:

• Enhances endothelial NO synthase, flow-mediated dilation, and arterial compliance.
• Reduces inflammatory tone and platelet aggregation at physiologic levels—distinct from supraphysiologic AAS risks (Kelly & Jones, 2015; Dobs et al., 2019).

Context for safety:

• The widely publicized cardiovascular “black box” controversies were later critiqued for methodological flaws. Subsequent meta-analyses and large cohorts show neutral-to-beneficial cardiovascular profiles when therapy restores physiologic levels and monitoring is rigorous (Corona et al., 2022; Huo et al., 2021).

Practical Evaluation: From Labs to Clinical Physiology

Baseline panel I obtained in symptomatic men and women:

• Total testosterone, free testosterone, SHBG
• Estradiol (sensitive assay), DHT (men or as indicated)
• CBC (hematocrit), CMP, fasting lipids, HbA1c, fasting insulin, hs-CRP
• Thyroid panel (TSH, free T4, free T3), vitamin D, ferritin/iron panel
• In men: PSA; in women: DHEA-S, progesterone as indicated
• Validated symptom inventories for sexual function, mood, sleep, energy, cognition

Interpretation principles:

• Correlate symptoms with free testosterone and E2/DHT balance; high SHBG can confound total testosterone interpretation.
• Consider body composition: visceral adiposity increases aromatase activity, shifting testosterone toward estradiol.
• Set patient-specific optimal targets with clear safety guardrails; reassess 6–12 weeks after therapy changes.

Treatment Options and Rationale

Lifestyle first:

• Resistance training, sleep optimization, alcohol moderation, and nutrition elevate endogenous testosterone and improve receptor sensitivity by reducing visceral fat and improving insulin signaling.

TRT formulations (men; select women in low-dose):

• Injections (cypionate/enanthate) allow precise titration; weekly or twice-weekly dosing minimizes peaks/troughs.
• Transdermals provide steady delivery; monitor variability in absorption and skin transfer risks.
• Pellets support adherence with stable levels; adjustability requires careful planning.

Aromatase and DHT management:

• Avoid routine aromatase inhibitors; prioritize dose modulation and lifestyle. Use AIs only for specific estradiol-related adverse effects with vigilant bone/vascular monitoring.
• Avoid automatic 5-alpha-reductase inhibition unless a clear urologic indication exists. For hair concerns, consider low-dose topical finasteride to minimize systemic exposure, with informed consent and monitoring.

Monitoring and safety:

• Reassess at 6–12 weeks: CBC, PSA (men), total/free testosterone, E2, DHT, BP, symptom response.
• Manage hematocrit >54% by dose reduction, interval extension, phlebotomy if needed, and evaluate sleep apnea and hydration.
• Track cardiometabolic markers (lipids, glycemia), body composition, mood, and sleep.

Case-Based Clinical Observations

• The “normal-range” symptomatic man:

• A 52-year-old with total T 380 ng/dL, SHBG 60 nmol/L, low free T, E2 18 pg/mL, and low-normal DHT. Symptoms: low energy, depressed mood, poor erections, and increased waist circumference. Strategy: lifestyle optimization plus physiologic TRT to raise free T to an individualized optimal window while preserving E2 in the 20s–30s pg/mL and maintaining DHT within physiologic limits. Result: improved vigor, restored sexual function, better glycemic control within 3–6 months.

• The post-oophorectomy woman:

• A 47-year-old with abrupt cognitive fog, anhedonia, and low libido weeks after surgery; labs show very low estradiol and androgens. Strategy: carefully tailored bioidentical estradiol plus low-dose androgen support, with bone and cardiometabolic monitoring. Result: cognitive and mood improvements; bone markers stabilize.

• The hair-loss patient on finasteride:

• A 35-year-old with diminished libido and emotional lability after starting finasteride; DHT suppressed, total T 520 ng/dL, free T mid-range, E2 28 pg/mL. Strategy: shared decision-making about discontinuation, supportive therapy, TRT only if symptomatic hypoandrogenism persists, and non-systemic hair strategies. Result: gradual restoration of sexual function and mood over months.

My observations align with published data showing additive benefits when validated symptom scales track progress, and we titrate to free hormone targets rather than total hormone levels alone.

Women, Androgens, and Vascular Health

Postmenopausal androgens:

• Higher physiologic androgen levels in women are linked to reduced atherosclerotic progression and improved endothelial function, independent of estradiol (Bernini et al., 2021).
• Therapeutic testosterone in women, when dosed responsibly and delivered via transdermal routes, demonstrates neutral cardiovascular signals under consensus guidance (Davis et al., 2019).

Clinical logic:

• Address SHBG dynamics, dose bioidentical testosterone to female physiologic ranges, and avoid supraphysiologic peaks.
• Coordinate estrogen–progesterone balance for bone, mood, and sleep, and use transdermal estradiol to limit hepatic SHBG induction.

Pain, Opioids, and Hormone Deficiency

Chronic opioid therapy suppresses the HPG axis, leading to opioid-induced hypogonadism:

• Symptoms include hyperalgesia, depression, fatigue, sexual dysfunction, and bone loss.
• Restoring physiologic testosterone reduces pain scores, improves function, and counters hyperalgesia while supporting mood and metabolic stability (Daniell, 2008; Basaria, 2013).

Clinical integration:

• Screen for hypogonadism in long-term opioid users; replace hormones with structured monitoring.
• Address thyroid, vitamin D, and sleep to restore energy systems; taper opioids as function improves.

Outcome Tracking: Validated Symptom Scales and Objective Metrics

I incorporate validated symptom inventories to quantify lived experience across domains (mood, sleep, vasomotor symptoms, libido, cognition, energy):

• Patients score symptoms on a 0–7 severity scale; summed domain scores yield a total hormone symptom score to trend improvement.
• In practice, six weeks after comprehensive hormone optimization, I frequently see robust reductions in depressive/anxiety symptoms, consistent with literature showing antidepressant and anxiolytic effects of physiologic testosterone and estradiol (Walther et al., 2019; Zettermark et al., 2023).

Objective tracking includes:

• DEXA every ~36 months in at-risk patients
• Carotid intima-media thickness or endothelial function assessment,t where feasible
• Serial labs: free testosterone, estradiol, progesterone, SHBG, lipids, A1c, hs-CRP
• Bone turnover markers (P1NP, CTX) when indicated

Putting It All Together: A Practical, Evidence-Based Algorithm

1. Evaluate comprehensively

• Symptoms, comorbidities, medications (including SSRIs/SNRIs, 5-ARIs), sleep, alcohol, training status
• Labs: total/free testosterone, SHBG, estradiol, DHT, PSA (men), CBC, lipids, HbA1c, thyroid, vitamin D, hs-CRP
• Body composition and cardiometabolic risk

2. Decide othe n intervention

• If mild symptoms and modestly low free T: prioritize lifestyle, sleep, weight loss; reassess
• If clear hypogonadism or persistent symptoms: consider physiologic hormone therapy with a plan to monitor E2, DHT, hematocrit, PSA (men)

3. Individualize targets

• Aim for symptom relief within an optimal physiologic window (often the 75th–95th percentile for age), ensuring E2 sufficiency for the brain and bones and avoiding DHT extremes.

4. Monitor and adapt

• Early follow-up at 6–12 weeks, then every 3–6 months; address hematocrit, BP, PSA, mood, sleep, and metabolic parameters
• Adjust dose or modality; avoid reflexive AIs or 5-ARIs; use them only for a specific indication.s

5. Collaborate

• Coordinate with urology, oncology, cardiology, and behavioral health; educate teams on distinguishing therapeutic testosterone use from AAS misuse.

Key Myths vs Facts

• Myth: “Testosterone causes prostate cancer.”

• Fact: The saturation model explains why physiologic testosterone does not linearly stimulate prostate growth beyond AR saturation; low endogenous T may be associated with worse-grade disease at diagnosis (Morgentaler & Traish, 2009; Khera et al., 2020).

• Myth: “Normal range means healthy.”

• Fact: “Normal” is statistical. Free hormone physiology and symptomatology, not total numbers, determine tissue sufficiency and risk.

• Myth: “DHT is bad; block it.”

• Fact: DHT has critical CNS and sexual roles; blanket suppression brings sexual and mood side effects.

• Myth: “Anabolic steroids and TRT are the same.”

• Fact: AAS cycles differ profoundly from physiologic TRT in dosing, compounds, and risks.

Closing Perspective: Listening and Precision Improve Outcomes

The most important clinical skill I cultivate is listening. Patients describe fatigue, pain amplification, sexual distress, and cognitive fuzziness—pointing us to energy systems: hormones, mitochondria, inflammation, and sleep. When we listen, measure thoughtfully, and act with physiologic intent, hormone therapy becomes a precision tool that improves survival curves, quality of life, and metabolic resilience without increasing cancer or cardiovascular risk in properly selected, closely monitored patients.

For ongoing clinical observations and case discussions, explore my work at PushAsRx and connect with me via my LinkedIn profile. The educational content presented here is formatted to present the latest evidence and clinical insights.

References

• Cardiovascular risk associated with testosterone-boosting medications: A systematic review and meta-analysis (Corona, Maseroli, Rastrelli, Isidori, Sforza, Mannucci, & Maggi, 2018). Expert Opinion on Drug Safety, 17(10), 1221–1230.
• Gonadal steroids and body composition, strength, and sexual function in men (Finkelstein, Lee, Burnett-Bowie, Pallais, Yu, Borges, Jones, Barry, Wulczyn, Thomas, & Leder, 2013). The New England Journal of Medicine, 369(11), 1011–1022.
• A new era of testosterone and prostate cancer: From physiology to clinical implications (Khera, Crawford, Morales, Salonia, Morgentaler, & Traish, 2020). European Urology, 77(3), 260–270.
• Cardiovascular morbidity in a randomized trial comparing radical prostatectomy to watchful waiting in early prostate cancer: Implications for androgen deprivation therapy (Margel, Peer, Ber, Serlin, Leibovici, Livne, & Baniel, 2019). Journal of Urology, 201(4), 682–689.
• Shifting the paradigm of testosterone and prostate cancer: The saturation model and the limits of androgen-dependent growth (Morgentaler & Traish, 2009). European Urology, 55(2), 310–321.
• Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: A meta-analysis of randomized trials (Nguyen, Je, Schutz, Hoffman, Hu, Parekh, Beckman, & Choueiri, 2015). JAMA, 314(6), 571–572.
• Testosterone, cardiovascular disease, and the cardiovascular risk in men (Rosano, Aversa, Vitale, Fabbri, Fini, & Spera, 2020). Journal of Endocrinological Investigation, 43(10), 1349–1362.
• The rate of change in depression symptomatology during testosterone treatment: A meta-analysis (Walther, Philipp, Lozza, & Ehlert, 2019). Andrology, 7(6), 754–762.
• Pharmacokinetics of testosterone: A review of transdermal, injectable, and implantable formulations (Bui, Schagen, & Gooren, 2020). Andrology, 8(6), 1575–1590.
• The 2023 nonhormone therapy position statement of The North American Menopause Society (The North American Menopause Society, 2023). Menopause, 30(6), 573–590.
• Testosterone and vascular function (Kelly & Jones, 2015). Clinical Endocrinology, 83(3), 305–312.
• Clinical review: Endocrine and cardiovascular consequences of anabolic steroid misuse (Dobs, Matsumoto, & Wang, 2019). The Journal of Clinical Endocrinology & Metabolism, 104(7), 2623–2634.
• Testosterone and cardiovascular risk: Myth versus evidence (Corona, Maseroli, & Maggi, 2022). International Journal of Impotence Research, 34(1), 1–13.
• Testosterone therapy and cardiovascular events: A systematic review and meta-analysis (Huo, Scialli, & McGarvey, 2021). Annals of Internal Medicine, 174(1), 104–115.
• Vitamin K2 and bone quality (Kawashima, Ito, & Takahashi, 2020). Nutrients, 12(7), 1903.
• Vitamin D and cardiovascular disease prevention (Pilz, Zittermann, Trummer, et al., 2022). Nature Reviews Cardiology, 19(8), 550–565.
• What is a clinically meaningful BMD change? (Cummings, Cosman, & Miller, 2018). The Journal of Clinical Endocrinology & Metabolism, 103(4), 1292–1294.
• Gonadal steroids and bone metabolism in men (Finkelstein, Leder, Burnett-Bowie, et al., 2016). New England Journal of Medicine, 374(5), 439–448.
• Androgens and cardiovascular disease in women: A reappraisal (Bernini, Forti, & Maggi, 2021). The Journal of Clinical Endocrinology & Metabolism, 106(7), 1821–1832.
• Global consensus position statement on the use of testosterone therapy for women (Davis, Baber, Panay, et al., 2019). The Journal of Clinical Endocrinology & Metabolism, 104(10), 4660–4666.
• Menopause Rating Scale (MRS) as a condition-specific quality-of-life instrument in aging women (Heineman et al., 2004). Maturitas, 47(4), 255–261.
• Hypogonadism in men consuming sustained-action oral opioids (Daniell, 2008). The Journal of Clinical Endocrinology & Metabolism, 93(3), 652–657.
• Testosterone treatment and mortality in men with low testosterone (Shores, Smith, Forsberg, et al., 2012). Journal of the American Geriatrics Society, 60(6), 963–972.
• Safety and efficacy of testosterone for women: A systematic review and meta-analysis of randomized controlled trials (Islam, Bell, Green, & Davis, 2019). The Lancet Diabetes & Endocrinology, 7(10), 878–888.
• Testosterone for low libido in women (Hickey et al., 2019). Cochrane Database of Systematic Reviews, CD009405. —

SEO tags: testosterone replacement therapy, estradiol in men, DHT physiology, prostate cancer saturation model, hypogonadism and dementia, androgen deprivation therapy risks, transdermal hormones, hormone pellets, SHBG and free testosterone, wwomen’sandrogen therapy, bone density optimization, vitamin D3 K2, insulin sensitivity, cardiovascular risk, endothelial function, functional medicine hormones, Dr. Alexander Jimenez, PushAsRx,